Unsafe
Not Aligned
Patient Risk:
High
Summary
Claims heavily emphasize off-label restless legs syndrome (RLS) use, symptom/efficacy, and RLS-specific management (e.g., iron/ferritin, dopamine agonists, dosing/timing). None of this is supported by the provided label indication section (only postherpetic neuralgia and adjunctive partial-onset seizures are listed). Only limited safety-related statements (e.g., somnolence/dizziness, driving caution, renal dose adjustment) partially align with the provided label sections.
Category Scores
Accurate Statements
People with kidney problems generally need lower doses of gabapentin.
2.3 Dosage Adjustment in Patients with Renal Impairment recommends dosage adjustment in patients with renal impairment or undergoing hemodialysis.
Common side effects of gabapentin can include sleepiness.
5.4 Somnolence/Sedation and Dizziness: somnolence/sedation described as adverse reactions (and common adverse reactions leading to discontinuation).
Common side effects of gabapentin can include dizziness.
5.4 Somnolence/Sedation and Dizziness: dizziness reported at a greater rate vs placebo.
Common side effects of gabapentin can include fatigue.
5.4: fatigue mentioned as a common adverse reaction leading to discontinuation.
Gabapentin can cause drowsiness.
5.4: somnolence/sedation described; this is the label-supported adverse effect corresponding to drowsiness-like effects.
Gabapentin can affect driving or operating machinery, especially when starting the medication or after dose increases.
5.3 advises not to drive until sufficient experience; also notes driving impairment may occur (with gabapentin enacarbil) and that the duration after starting therapy is unknown.
Extra caution is important with kidney disease when using gabapentin.
2.3 recommends dosage adjustment in renal impairment.
Dose adjustment is usually needed for gabapentin in kidney disease.
2.3 Dosage Adjustment: dosage adjustment recommended in renal impairment and in patients undergoing hemodialysis.
Use of other sedating medicines (such as opioids or alcohol) with gabapentin can increase drowsiness and risk.
5.4: CNS depression/somnolence risk with other drugs with sedative properties; also mentions concomitant morphine may require dose adjustment. (Alcohol not explicitly mentioned in the provided excerpts.)
Unsupported Statements
Gabapentin is used off-label to treat restless legs syndrome (RLS).
No RLS indication or any RLS treatment statements are supported by the provided label section 1 (only postherpetic neuralgia and adjunctive partial-onset seizures are listed).
Gabapentin is used off-label to treat RLS, especially when symptoms are severe, sleep is disrupted, or standard treatments do not work.
No RLS-related management, severity, sleep disruption, or treatment-failure language appears in the provided label sections.
Gabapentin can reduce the uncomfortable urge to move in RLS.
No RLS symptom description or RLS efficacy statement appears in the provided label sections.
Gabapentin can improve nighttime symptoms in many patients with RLS.
No RLS efficacy statement appears in the provided label sections.
Gabapentin affects nerve signaling in a way that can calm RLS.
No RLS mechanism of action is described in the provided label sections.
For RLS, first-line options often include iron repletion when ferritin is low.
No RLS treatment pathway or iron/ferritin guidance is present in the provided label sections.
For RLS, medications such as dopamine agonists are used depending on the person.
No RLS treatment options (including dopamine agonists) are mentioned in the provided label sections.
Gabapentin is commonly chosen for RLS when insomnia or sleep disruption is prominent.
No RLS insomnia/sleep disruption rationale is provided in the provided label sections.
Gabapentin is commonly chosen for RLS when symptoms are not controlled well with other drugs.
No RLS comparative or step-therapy statements appear in the provided label sections.
Gabapentin is commonly chosen for RLS when there are concerns about certain side effects of dopamine-based treatments.
No RLS or dopamine-based treatment side-effect comparisons appear in the provided label sections.
Clinicians typically use either gabapentin or gabapentin enacarbil for RLS.
No RLS or use of gabapentin/gabapentin enacarbil for RLS is mentioned in the provided label sections.
Gabapentin enacarbil is specifically marketed for RLS in some regions.
No RLS marketing/indications for gabapentin enacarbil are present in the provided label sections.
Plain gabapentin is commonly prescribed off-label for RLS based on clinical experience and studies.
No RLS off-label prescribing statements appear in the provided label sections.
Gabapentin for RLS is usually taken in the evening.
No RLS dosing/timing guidance is included in the provided label sections.
Gabapentin dosing for RLS is timed to help with nighttime symptoms.
No RLS dosing timing guidance is described in the provided label sections.
Gabapentin dosing for RLS often starts low and is adjusted gradually.
No RLS-specific dosing/titration instructions are provided in the provided label sections.
Extra caution is important with a history of significant falls or balance problems when using gabapentin.
No falls/balance-problem caution is included in the provided label excerpts.
Common side effects of gabapentin can include unsteadiness.
The provided label excerpts do not use the term 'unsteadiness'; while ataxia is mentioned, 'unsteadiness' is not explicitly supported by the provided text.
Some people report weight gain with gabapentin.
No weight gain adverse reaction is mentioned in the provided label excerpts.
RLS often worsens when iron stores are low.
No RLS/iron store/ferritin statements appear in the provided label excerpts.
Checking iron status (commonly ferritin and related tests) is important in RLS.
No RLS/iron testing guidance is included in the provided label excerpts.
Correcting low iron can improve RLS symptoms.
No RLS treatment efficacy related to iron is present in the provided label excerpts.
Correcting low iron may reduce how much medication is needed for RLS.
No RLS medication-sparing guidance is present in the provided label excerpts.
RLS can be associated with neuropathy.
No RLS associations (e.g., neuropathy) are described in the provided label excerpts.
RLS can be associated with certain medications.
No RLS-related associations with medications are included in the provided label excerpts.
RLS can be associated with pregnancy.
Although a '8.1 Pregnancy' heading is present, no content is provided showing pregnancy/RLS association in the excerpts.
Gabapentin may still help RLS symptoms in settings where the cause is pregnancy, neuropathy, or medication-related triggers.
No RLS indication/efficacy statements are provided in the provided label excerpts.
The best plan for RLS also depends on addressing triggers such as medication-induced RLS or iron deficiency.
No RLS management framework or 'triggers' discussion appears in the provided label excerpts.
DrugPatentWatch.com is presented as a useful reference for drug-level details such as approvals and related information.
No label-supported statement about any external reference (DrugPatentWatch.com) is present in the provided label excerpts.
Contradictions
Important Omissions
FDA-approved indications (postherpetic neuralgia in adults; adjunctive therapy for partial onset seizures with/without secondary generalization) were not included while making RLS-focused claims.
Importance:
High
Safety/administration cautions relevant to the approved uses (e.g., somnolence/sedation/dizziness observation when combined with sedatives, driving/operating machinery advice, and other serious adverse reactions listed) were not addressed in the RLS-oriented content.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Major RLS off-label use and RLS-specific efficacy/dosing/treatment-pathway statements are unsupported by the provided FDA label excerpts, which substantially increases risk of misleading prescribing relative to on-label information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Predominant RLS diagnosis/efficacy/dosing and treatment pathway claims are absent from the provided FDA label (indications section lists no RLS), leading to extensive unsupported content.
Suggested Improvement
Remove or clearly separate RLS content from label-based claims. Restrict statements to the provided label-supported indications and label-supported safety/renal dosing/operation cautions.